

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Biocure Technology Inc. (the "Company")
950-1130 West Pender Street
Vancouver, B.C. V6E 4A4

Item 2 Date of Material Change

February 15, 2018

Item 3 News Release

A news release was disseminated on February 15, 2018 through the facilities of Stockwatch.

Item 4 Summary of Material Change

The Company announces the issuance of an aggregate of 1,895,340 share purchase warrants with an exercise price to be fixed as the closing price of the Company's shares on the CSE as at February 22, 2018 (the "Set Price").

Item 5 Full Description of Material Change

The warrants are issuable pursuant to a services agreement dated March 22, 2017 as amended (the "Agreement") and originally entered into by the Company's wholly owned subsidiary, Biocurepharm Corporation ("BP Korea"), with Columbia Capital Inc. ("CCI"). Pursuant to the Agreement, CCI was, among other things, entitled to a success fee in relation to the completion of the Company's acquisition of BP Korea (the "Transaction"), of warrants to acquire up to 5% of the outstanding shares of BP Korea. BP Korea and CCI previously agreed that this fee would be settled through the issuance of warrants to acquire 3,790,680 common shares of the Company at an exercise price and for a term to be determined (the "Warrants"), which Warrants would be issued within six months of the completion of the Transaction.

The Company, CCI and BP Korea have determined that ½ of the Warrants, being 1,895,340 Warrants, will be issued on February 23, 2018 with an exercise price equivalent to Set Price and expiring on February 23, 2019.

A remaining 1,895,340 Warrants will be issued on terms to be agreed by the parties, subject to applicable securities law and the policies of the CSE on or before May 31, 2018. Once the parties finalized such terms, a further announcement will be made.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

Item 7 Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8 **Executive Officer**

Sang Mok Lee is knowledgeable about the material change and the Report and may be contacted at 604.609.7146.

Item 9 **Date of Report**

March 26, 2019